Home › Blood Clots › NCT02972385
Pharmacogenomics of Warfarin in Hispanics and Latinos
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * At least 18 years of age * Ability to give informed consent * Therapeutic INR for at least 2 consecutive clinic visits * Self-identifies as Hispanic or Latino Exclusion Criteria: * Less than 18 years old * Unable to give informed consent * Severe hepatic impairment
About the study
Warfarin is a commonly used blood thinner to treat and prevent blood clots. It is important to take the right dose of warfarin because too much can increase the risk of bleeding and too little can increase the risk of blood clots. This is why patients are closely monitored especially when they begin warfarin therapy. When clinicians prescribe warfarin, they have to consider different factors such as patient's age, body size, diet, and other medications that can interact with warfarin.
Certain genes have also been found to affect warfarin dose. Individuals have variations in these genes, which can help explain why some patients need higher dose and others require less. These factors have been used to better predict a patient's warfarin dose requirement. However, these predictions were created based on Caucasian populations and they may not be accurate in predicting a safe warfarin dose if a patient is not Caucasian. This study aims to identify new genetic variation that affects warfarin dosing in Hispanic and Latino populations and try to better predict a Hispanic or Latino patient's warfarin dose requirement.
What is being tested
- Mouthwash sample (procedure)
- Blood Draw (procedure)
Sponsor: University of Arizona · Participants: 400 · Started: 2016-09
Contact the study team
- Jason H Karnes, PharmD, PhD · Phone: 520-626-1447
- Talin A Robinson Catalan, MS · Phone: 520-278-6114
Official record on ClinicalTrials.gov — NCT02972385
Locations in the U.S.
| Arizona | Banner University Medical Center - Tucson, Tucson |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.